+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Contralateral, ipsilateral and bilateral treatments with the kappa-opioid receptor agonist U-50,488H in mononeuropathic rats



Contralateral, ipsilateral and bilateral treatments with the kappa-opioid receptor agonist U-50,488H in mononeuropathic rats



European Journal of Pharmacology 494(2-3): 139-146



The effect of repeated contralateral administration of the kappa-opioid receptor agonist U-50,488H (trans-(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzeneacetamide methanesulfonate) on nociceptive behaviour was investigated and compared with ipsilateral and bilateral treatments in a rat model of peripheral unilateral neuropathy (chronic constriction of the common sciatic nerve). Administration of 0.3 mg U-50,488H into the contralateral hindpaw on days 6 and 10 after induction of mononeuropathy increased hindpaw withdrawal latency to mechanical but not to thermal stimulation compared to saline-treated rats. No difference in pain-related behaviour was found between different peripheral (contralateral, ipsilateral and bilateral) treatments with 0.3 mg U-50,488H. Autotomy behaviour was reduced for 6 weeks after sciatic nerve ligation in rats treated contralaterally with the opioid receptor agonist. Antinociceptive effects of contralaterally administered U-50,488H were abolished by the peripherally acting opioid receptor antagonist naloxone methiodide. Our findings indicate that contralateral treatment with U-50,488H attenuates nociceptive behaviour in mononeuropathic rats. These antinociceptive effects are mediated via peripheral opioid receptors.

(PDF emailed within 0-6 h: $19.90)

Accession: 048647984

Download citation: RISBibTeXText

PMID: 15212967

DOI: 10.1016/j.ejphar.2004.04.043


Related references

Contralateral, ipsilateral and bilateral treatments with the K-opioid receptor agonist U-50,488H in mononeuropathic rats. European Journal of Pharmacology 494(2-3): 139-146, June 28, 2004

Anti-inflammatory effects of contralateral administration of the kappa-opioid agonist U-50,488H in rats with unilaterally induced adjuvant arthritis. Rheumatology 45(3): 295-302, 2006

Anti-inflammatory effects of contralateral administration of the kappa-opioid agonist U-50,488H in rats with unilaterally induced adjuvant arthritis. Rheumatology 45(3): 295-302, 2005

Contralateral but not systemic administration of the kappa-opioid agonist U-50,488H induces anti-nociception in acute hindpaw inflammation in rats. British Journal of Pharmacology 132(1): 252-258, 2001

The kappa opioid agonist U-50,488H antagonizes respiratory effects of mu opioid receptor agonists in conscious rats. Journal of Pharmacology and Experimental Therapeutics 264(2): 631-637, 1993

Effects of U-50,488H on isolated atria from rats chronically treated with the kappa-opioid agonist, U-50,488H. Journal of Autonomic Pharmacology 18(6): 371-375, 1999

Peripheral component in the enhanced antinociceptive effect of systemic U-69,593, a kappa-opioid receptor agonist in mononeuropathic rats. European Journal of Pharmacology 357(2-3): 171-178, 1998

Effect of chronic administration of naltrexone on brain mu- and kappa-opioid receptors and responses to U-50,488H, a kappa-opioid receptor agonist in the mouse. FASEB Journal 9(3): A102, 1995

Inhibitory effect of a selective kappa receptor agonist, U-50, 488H, on methamphetamine-elicited ipsilateral circling behavior in rats with unilateral nigral lesions. Psychopharmacology 97(2): 219-221, 1989

Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice. European Journal of Pharmacology 321(3): 265-271, 1997

Inhibition by a kappa-opioid receptor agonist (U50,488H) of electrically-stimulated oxytocin secretion from the neurohypophysis in anaesthetized lactating rats. Journal of Physiology 401: 34P, 1988

Modification of the binding of [3H]MK-801 to brain regions and spinal cord of rats treated chronically with U-50,488H, a kappa-opioid receptor agonist. Brain Research 749(2): 347-350, 1997

U-50,488H, a selective kappa opioid receptor agonist, ameliorates memory impairments induced by muscarinic autoreceptor agonist, carbachol in mice. Neuroscience Letters 236(1): 45-48, 1997

Blockade of ethanol reward by the kappa opioid receptor agonist U50,488H. Alcohol 43(5): 359-365, 2009

Attenuation of the antinociceptive action of the selective kappa-opioid receptor agonist, U-50,488H by ICS-205-930. European Journal of Pharmacology 178(3): 371-373, 1990